Tests petrelintide against placebo for weight management in adults with obesity
Tests petrelintide, a once-weekly drug, in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
Key facts
- Where
- Florence, Milan, Palermo, and Pisa, ItalySee the 5 sites
- Phase
- Phase 3
Where in Italy
- Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyNot yet recruiting
- Centro Cardiologico Monzino S.p.A.Milan, ItalyNot yet recruiting
- Ospedale San Raffaele S.r.l.Milan, ItalyNot yet recruiting
- Azienda Ospedaliera Universitaria Policlinico Paolo GiacconePalermo, ItalyNot yet recruiting
- Azienda Ospedaliero Universitaria PisanaPisa, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07843498EU 2026-526188-39-00
- Record updated
- 5 November 2026
- Original description
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, and without Type 2 Diabetes (T2D).Read full original descriptionShow less
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, and without Type 2 Diabetes (T2D).
Inclusion: Participants with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Current or previous treatment with petrelintide or any other amylin analog; Known history of Type 1 or Type 2 diabetes mellitus; HbA1c ≥ 48 mmol/mol (6.5%), measured by the central laboratory at screening.